Literature DB >> 24920658

RNAi therapies: drugging the undruggable.

Sherry Y Wu1, Gabriel Lopez-Berestein2, George A Calin2, Anil K Sood3.   

Abstract

RNA interference (RNAi) therapy is a rapidly emerging platform for personalized cancer treatment. Recent advances in small interfering RNA delivery and target selection provide unprecedented opportunities for clinical translation. Here, we discuss these advances and present strategies for making RNAi-based therapy a viable part of cancer management.
Copyright © 2041, American Association for the Advancement of Science.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24920658      PMCID： PMC4154139          DOI： 10.1126/scitranslmed.3008362

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  26 in total

1.  Lipid-like materials for low-dose, in vivo gene silencing.

Authors:  Kevin T Love; Kerry P Mahon; Christopher G Levins; Kathryn A Whitehead; William Querbes; J Robert Dorkin; June Qin; William Cantley; Liu Liang Qin; Timothy Racie; Maria Frank-Kamenetsky; Ka Ning Yip; Rene Alvarez; Dinah W Y Sah; Antonin de Fougerolles; Kevin Fitzgerald; Victor Koteliansky; Akin Akinc; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

2.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.

Authors:  Lydia Alvarez-Erviti; Yiqi Seow; Haifang Yin; Corinne Betts; Samira Lakhal; Matthew J A Wood
Journal:  Nat Biotechnol       Date:  2011-03-20       Impact factor: 54.908

3.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

4.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Authors:  Charles N Landen; Arturo Chavez-Reyes; Corazon Bucana; Rosemarie Schmandt; Michael T Deavers; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

Review 5.  siRNA and innate immunity.

Authors:  Marjorie Robbins; Adam Judge; Ian MacLachlan
Journal:  Oligonucleotides       Date:  2009-06

6.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

7.  First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

Authors:  Josep Tabernero; Geoffrey I Shapiro; Patricia M LoRusso; Andres Cervantes; Gary K Schwartz; Glen J Weiss; Luis Paz-Ares; Daniel C Cho; Jeffrey R Infante; Maria Alsina; Mrinal M Gounder; Rick Falzone; Jamie Harrop; Amy C Seila White; Iva Toudjarska; David Bumcrot; Rachel E Meyers; Gregory Hinkle; Nenad Svrzikapa; Renta M Hutabarat; Valerie A Clausen; Jeffrey Cehelsky; Saraswathy V Nochur; Christina Gamba-Vitalo; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Howard A Burris
Journal:  Cancer Discov       Date:  2013-01-28       Impact factor: 39.397

8.  Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.

Authors:  Cheng-Qiong Mao; Meng-Hua Xiong; Yang Liu; Song Shen; Xiao-Jiao Du; Xian-Zhu Yang; Shuang Dou; Pei-Zhuo Zhang; Jun Wang
Journal:  Mol Ther       Date:  2014-02-05       Impact factor: 11.454

9.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size.

Authors:  H Cabral; Y Matsumoto; K Mizuno; Q Chen; M Murakami; M Kimura; Y Terada; M R Kano; K Miyazono; M Uesaka; N Nishiyama; K Kataoka
Journal:  Nat Nanotechnol       Date:  2011-10-23       Impact factor: 40.523

10.  In vivo selection of tumor-targeting RNA motifs.

Authors:  Jing Mi; Yingmiao Liu; Zahid N Rabbani; Zhongguang Yang; Johannes H Urban; Bruce A Sullenger; Bryan M Clary
Journal:  Nat Chem Biol       Date:  2009-11-29       Impact factor: 15.040
View more
  75 in total

1.  Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.

Authors:  Hiroto Hatakeyama; Sherry Y Wu; Lingegowda S Mangala; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Methods Mol Biol       Date:  2016

2.  Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).

Authors:  Michael J Wagner; Rahul Mitra; Mark J McArthur; Wallace Baze; Kirstin Barnhart; Sherry Y Wu; Cristian Rodriguez-Aguayo; Xinna Zhang; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2017-03-06       Impact factor: 6.261

3.  Properties of Native High-Density Lipoproteins Inspire Synthesis of Actively Targeted In Vivo siRNA Delivery Vehicles.

Authors:  Kaylin M McMahon; Michael P Plebanek; C Shad Thaxton
Journal:  Adv Funct Mater       Date:  2016-09-20       Impact factor: 18.808

4.  The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA.

Authors:  Haitang Wang; Yuen Yi C Tam; Sam Chen; Josh Zaifman; Roy van der Meel; Marco A Ciufolini; Pieter R Cullis
Journal:  Mol Ther       Date:  2016-09-16       Impact factor: 11.454

5.  Rosmarinic acid and siRNA combined therapy represses Hsp27 (HSPB1) expression and induces apoptosis in human glioma cells.

Authors:  Aslıhan Şengelen; Evren Önay-Uçar
Journal:  Cell Stress Chaperones       Date:  2018-04-07       Impact factor: 3.667

Review 6.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

7.  Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease.

Authors:  Jonathan Wang; Jacqueline J Masehi-Lano; Eun Ji Chung
Journal:  Biomater Sci       Date:  2017-07-25       Impact factor: 6.843

Review 8.  Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.

Authors:  Wolfgang Poller; Stefanie Dimmeler; Stephane Heymans; Tanja Zeller; Jan Haas; Mahir Karakas; David-Manuel Leistner; Philipp Jakob; Shinichi Nakagawa; Stefan Blankenberg; Stefan Engelhardt; Thomas Thum; Christian Weber; Benjamin Meder; Roger Hajjar; Ulf Landmesser
Journal:  Eur Heart J       Date:  2018-08-01       Impact factor: 29.983

9.  Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles.

Authors:  Yijuan Zhang; Marissa Leonard; Yi Shu; Yongguang Yang; Dan Shu; Peixuan Guo; Xiaoting Zhang
Journal:  ACS Nano       Date:  2016-12-16       Impact factor: 15.881

10.  Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells.

Authors:  Yunfeng Yan; Li Liu; Hu Xiong; Jason B Miller; Kejin Zhou; Petra Kos; Kenneth E Huffman; Sussana Elkassih; John W Norman; Ryan Carstens; James Kim; John D Minna; Daniel J Siegwart
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-12       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.